SDGR

Schrodinger, Inc. (SDGR) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Schrodinger, Inc. operates a physics-based computational platform for drug discovery and materials science, generating revenue through software licensing and drug discovery collaborations. The company maintains two reportable segments: Software and Drug Discovery.

Key Financial Metrics

Note: Operating cash flow for YTD 2025 was positive $91.9 million, a significant improvement from the $93.0 million used in YTD 2024, driven largely by cash collections from the Novartis collaboration.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 16% year-over-year (Q2) and 36% year-over-year (YTD).
  • Software Revenue: Increased 15% (Q2) and 30% (YTD), driven by growth in hosted software subscriptions and contributions from the Bill & Melinda Gates Foundation.
  • Drug Discovery Revenue: Increased 19% (Q2) and 65% (YTD), primarily due to the commencement of the Novartis collaboration services in November 2024.
• Cost of Revenues: Increased significantly (79% Q2, 69% YTD) due to higher personnel, cloud computing, and CRO expenses, particularly related to the Novartis agreement and proprietary programs moving to partnered status.
• Operating Expenses: Total operating expenses decreased 6% (Q2) and 5% (YTD). Research and Development (R&D) expenses declined 15% (Q2) and 12% (YTD) due to a reduction in external costs for early-stage candidates and a workforce restructuring.
• Equity Investments: The company reported a change in fair value of equity investments of $4.6 million gain (Q2) and $8.5 million loss (YTD), primarily related to Structure Therapeutics.

Guidance, Outlook, and Management Commentary

• Restructuring: On May 19, 2025, the company restructured operations, reducing the workforce by approximately 60 employees (7% of headcount). This is expected to incur ~$3 million in charges and reduce annualized operating expenses by ~$30 million.
• Novartis Collaboration: A major driver of recent revenue. The company received a $150 million upfront payment (recognized in deferred revenue) and is eligible for up to $2.272 billion in milestones. No milestone revenue has been recognized as of June 30, 2025.
• Proprietary Pipeline:
  • SGR-1505 (MALT1 inhibitor): Phase 1 data reported in June 2025 showed the drug was well-tolerated with preliminary clinical activity. FDA granted Fast Track designation in June 2025 for Waldenström macroglobulinemia.
  • SGR-2921 (CDC7 inhibitor): Phase 1 dosing initiated; Fast Track designation granted in July 2024.
  • SGR-3515 (Wee1/Myt1 inhibitor): Phase 1 dosing initiated in July 2024.
• Liquidity: As of June 30, 2025, the company held $462.3 million in cash, cash equivalents, restricted cash, and marketable securities. Management believes this is sufficient to fund operations for at least the next 24 months.
• Tax Law Changes: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes changes to R&D expensing and bonus depreciation. The company is evaluating the impact but does not anticipate a material change to its effective tax rate due to its full valuation allowance.

Investor Verification Checklist

• Novartis Revenue Recognition: Verify the timing of revenue recognition for the $150 million upfront payment and the specific milestones triggering future revenue.
• Restructuring Savings: Monitor the realization of the projected $30 million annualized cost savings from the May 2025 workforce reduction.
• SGR-1505 Clinical Data: Review the full clinical data release for SGR-1505 to assess the durability of the 22% overall response rate and safety profile.
• Equity Investment Volatility: Track the fair value of the Structure Therapeutics investment, which caused significant non-cash fluctuations in net loss.
• Customer Concentration: Note that as of June 30, 2025, one customer accounted for 19% of total revenue and 19% of accounts receivable.